Risk-benefit assessment of glatiramer acetate in multiple sclerosis (Q34519776)

2 August 2017

title

Risk-benefit assessment of glatiramer acetate in multiple sclerosis (English)

1 reference

2 August 2017

0 references

1

T Ziemssen

1 reference

2 August 2017

O Neuhaus

2

1 reference

2 August 2017

R Hohlfeld

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

24

1 reference

2 August 2017

issue

13

1 reference

2 August 2017

page(s)

979-990

1 reference

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis

2 August 2017

cites work

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Therapeutic strategies in multiple sclerosis. I. Immunotherapy

1 reference

12 December 2020

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

12 December 2020

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

1 reference

12 December 2020

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

12 December 2020

Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone)

1 reference

12 December 2020

Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report

1 reference

12 December 2020

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

12 December 2020

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

Multiple sclerosis: trial of a synthetic polypeptide

1 reference

12 December 2020

Altered peptide ligands: prospects for immune intervention in autoimmune disease

1 reference

12 December 2020

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

12 December 2020

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center

1 reference

12 December 2020

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

1 reference

12 December 2020

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

12 December 2020

Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification

1 reference

12 December 2020

Lymphocyte responses and cytokines

1 reference

12 December 2020

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

12 December 2020

Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis

1 reference

12 December 2020

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

1 reference

12 December 2020

Th1-Th2: reliable paradigm or dangerous dogma?

1 reference

12 December 2020

A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data

1 reference

12 December 2020

Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein

1 reference

12 December 2020

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Systemic reaction to glatiramer acetate

1 reference

12 December 2020

Copolymer 1 from the laboratory to FDA.

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Clinical trials of copolymer I in multiple sclerosis

1 reference

12 December 2020

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

1 reference

12 December 2020

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment

1 reference

12 December 2020

Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate

1 reference

12 December 2020

Copolymer 1: from basic research to clinical application

1 reference

12 December 2020

Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

1 reference

12 December 2020

The expanding universe of T-cell subsets: Th1, Th2 and more.

1 reference

12 December 2020

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

12 December 2020

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation

1 reference

12 December 2020

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

1 reference

12 December 2020

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

1 reference

12 December 2020

Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

1 reference

12 December 2020

Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex

1 reference

12 December 2020

In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

1 reference

12 December 2020

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

12 December 2020

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability

1 reference

12 December 2020

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

12 December 2020

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

1 reference

12 December 2020

Copolymer 1 as therapy for multiple sclerosis: the cons

1 reference

12 December 2020

Localized lipoatrophy after prolonged treatment with copolymer 1

1 reference

12 December 2020

Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Protection against experimental allergic encephalomyelitis.

1 reference

12 December 2020

Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate

1 reference

12 December 2020

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

12 December 2020

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1 reference

12 December 2020

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

1 reference

12 December 2020

Human cellular immune response to copolymer I and myelin basic protein

1 reference

12 December 2020

Immunogenic potentials of copolymer I in normal human lymphocytes

1 reference

12 December 2020

Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.

1 reference

12 December 2020

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

12 December 2020

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

12 December 2020

Oral tolerance with copolymer 1 for the treatment of multiple sclerosis

1 reference

12 December 2020

10.2165/00002018-200124130-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1039992648

0 references

1 reference